Content
Grow Your Bottom Line As Demand Increases For These Robots
Article By:
Brad Thomas
Read
Saturday, April 6, 2024 12:20 PM EDT
Today, I’ll explain why there’s a growing need for more robots to do surgery. I’ll also show you how to collect a reliable yield while investing in a company that’s developing new surgical robots.
Is Amgen The Rare Biotech With A Safe Dividend?
Article By:
Marc Lichtenfeld
Read
Wednesday, April 3, 2024 8:10 PM EDT
Amgen pays a $2.25 per share quarterly dividend, which comes out to a 3.3% yield. Biotech can be notoriously volatile, though, so can investors count on receiving the same dividend quarter after quarter?
In this article: AMGN
Tuesday Talk: April Is The Cruelest Month?
Article By:
David Marshall
Read
Tuesday, April 2, 2024 8:25 AM EDT
At least that is what the poet T.S. Eliot wrote in the opening line of his well-known poem, "The Wasteland". With all the chatter about an April correction it might be, but traditionally April is one of the strongest months for the stock market.
ADUS: A Home Health Care Provider With Solid Growth
Article By:
MoneyShow.com
Read
Tuesday, April 2, 2024 12:18 AM EDT
Addus HomeCare Corp. posted a strong close to fiscal 2023. In Q4, revenues grew 11.9% to $276.4 million, while EPS increased 31.9% to $1.20.
In this article: ADUS
Addus HomeCare: A Home Health Care Provider With Solid Growth
Article By:
MoneyShow.com
Read
Saturday, March 30, 2024 6:54 PM EDT
Addus HomeCare Corp. posted a strong close to fiscal 2023. In Q4, revenues grew 11.9% to $276.4 million, while EPS increased 31.9% to $1.20. As of Dec. 31, 2023, the company had cash of $64.8 million and bank debt of $126.4 million.
In this article: ADUS
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Article By:
The Life Sciences Report
Read
Friday, March 29, 2024 10:12 PM EDT
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair loss.
In this article: NKTR
Walgreens Boots Alliance Shows Resilience In Q2 With $37.1B In Sales
Article By:
The Tokenist
Read
Thursday, March 28, 2024 9:27 AM EDT
Walgreens Boots Alliance demonstrated resilience and adaptability in its fiscal Q2, with a 6.3 percent increase in sales.
In this article: WBA
Elliott Wave Technical Analysis: Johnson & Johnson - Tuesday, March 26
Article By:
Peter Mathers
Read
Tuesday, March 26, 2024 10:40 AM EDT
The analysis reveals a trending function characterized by impulsive mode and motive structure, positioned in Wave (3).
In this article: JNJ